688109，停牌！筹划重大事项

Market Overview - On September 17, A-shares saw all three major indices rise, with the ChiNext Index increasing by nearly 2% and total trading volume in the Shanghai and Shenzhen markets reaching 24,029.24 billion yuan, an increase of over 35 billion yuan compared to the previous trading day [1] - More than 2,500 stocks closed higher, with 80 stocks hitting the daily limit up [1] - Key sectors that performed well included photolithography machines, copper cable high-speed connections, and flexible screens, while sectors such as duty-free shops and prepared dishes saw declines [1] Shareholder Dynamics - According to statistics, 733 companies reported their latest shareholder numbers as of September 10, with 103 stocks experiencing a continuous decline in shareholder numbers for more than three periods, with the most significant drop being 12 periods [2] - ST Huawen had the highest reduction in shareholder numbers, down 14.42% to 63,064, while *ST Jinglun saw a 36.88% decrease to 39,050 [2][3] - Notable companies with significant recent declines in shareholder numbers include Beifang Changlong, Hubei Broadcasting, and Pioneer Electronics, with reductions of 16.91%, 10.31%, and 10% respectively [3] Institutional Activity - In the latest trading session, 11 stocks were net bought by institutions, with Haoen Qidian and Weilan Lithium Chip each seeing net purchases exceeding 90 million yuan [4][5] - Conversely, Tianji Co. faced the highest net sell-off by institutions, amounting to 113 million yuan, followed by Baoxiniang and Bangji Technology, both exceeding 10 million yuan in net sales [4][6] Notable Announcements - Pinming Technology announced a stock suspension due to a major matter that may lead to a change in control [7] - Tianpu Co. completed its stock trading suspension review and will resume trading [7] - Pingzhi Information has pre-awarded a project for artificial intelligence computing power services worth approximately 170 million yuan [7] - Heng Rui Pharmaceutical's HRS-5635 injection has been included in the list of proposed breakthrough treatment varieties [8] - Maiwei Bio-U signed an exclusive licensing agreement with Kalexo, potentially receiving up to 1 billion USD in upfront and milestone payments [9]